<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878342</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0107/1803</org_study_id>
    <nct_id>NCT03878342</nct_id>
  </id_info>
  <brief_title>Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast</brief_title>
  <acronym>ROMANCE</acronym>
  <official_title>Prospective Study of Omission of Whole-breast Radiotherapy Following Breast-conserving Surgery in Patients With Very Low Risk Ductal Carcinoma in Situ of the Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following breast-conserving surgery (BCS) for localized ductal carcinoma in situ (DCIS) of&#xD;
      the breast, whole-breast irradiation (WBRT) is a standard of care, reducing the absolute rate&#xD;
      of in-breast recurrences (IBR) by more than 15% at 10 years, from 28% without radiotherapy to&#xD;
      13 % with radiotherapy. Half of the recurrences occurred as invasive disease. Whereas in the&#xD;
      comparative trials, WBRT did not impact on overall survival, survival of patients who&#xD;
      recurred with invasive cancers was impaired in comparison to patients who did not recur, or&#xD;
      to patients with DCIS-only recurrences.&#xD;
&#xD;
      Using criteria based on age, tumor size, nuclear grade, and margins status, several trials&#xD;
      and cohort studies failed to identify subgroups of patients at low risk, who could be safely&#xD;
      spared the need for WBRT. The Radiation Therapy Oncology Group (RTOG) DCIS trial included&#xD;
      patients treated with BCS for low- or intermediate grade DCIS revealed by unifocal&#xD;
      microcalcifications, size ≤25 mm, margins ≥3 mm, and no residual microcalcifications after&#xD;
      surgery. The 5-year rates of IBR were 3.5 % without radiotherapy, versus 0.4 % with&#xD;
      radiotherapy, and 6.7 % and 0.9 % at 7 years, respectively (p &lt;0.001). Sixty percent of the&#xD;
      patients received tamoxifen in both groups.&#xD;
&#xD;
      Several studies showed that the same molecular classes were identified in DCIS as in invasive&#xD;
      cancers. Studies suggested that low proliferation, hormone receptors expression, and lack of&#xD;
      ERBB2 amplification were associated with a low risk of IBR in patients not receiving&#xD;
      radiotherapy. A combined signature was tested in the Eastern Cooperative Oncology Group&#xD;
      (ECOG) trial, showing a 10% IBR rate at ten years in patients with a low-risk.&#xD;
&#xD;
      Identifying very low-risk DCIS, using biological markers in addition to the clinical and&#xD;
      histological markers of low-risk DCIS, could help to select patients who could be safely&#xD;
      avoided WBRT following BCS. It would avoid over-treatment in these women and could decrease&#xD;
      the cost of management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Anticipated">July 27, 2032</completion_date>
  <primary_completion_date type="Anticipated">June 27, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-year cumulative incidence of in-breast cancer recurrences</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of breast recurrence is determined from the date of last surgery to the date of breast recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>10 years</time_frame>
    <description>OS is defined as the interval between the date of last surgery and the date of death from any cause;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast cancer-specific survival (BCSS)</measure>
    <time_frame>10 years</time_frame>
    <description>BCSS is defined as the interval between the date of last surgery and the date of death from breast cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>10 years</time_frame>
    <description>RFS is defined as the interval between the date of last surgery and the date of ipsilateral breast recurrence, regional nodes recurrence, distant metastases, of death from breast cancer, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of in-breast recurrences (IBR).</measure>
    <time_frame>10 years</time_frame>
    <description>In-breast recurrence defined as any carcinoma (invasive or in situ) occurring in the treated breast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Contralateral breast</measure>
    <time_frame>10 years</time_frame>
    <description>Contralateral breast cancer defined as any carcinoma (invasive or in situ) occurring in the contralateral breast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the patients using EORTC-QLQ-C 30</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of life will be assessed using QLQ-C 30 questionnaire from the European Organization for Research and Treatment of Cancer (EORTC). It is a 30-item self-reporting questionnaire developed to assess the quality of life of cancer patients. It is grouped into five functional subscales (role, physical, cognitive, emotional and social functioning). In addition, there are three multi-item symptom scales (fatigue, pain, and nausea and vomiting), individual questions concerning common symptoms in cancer patients,and two questions assessing overall Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the patients using EORTC-QLQ-BR23</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of Life of Patients will be assessed using a EORTC-QLQ BR23.It is a 23-item self-reporting specific questionnaire developed to assess the quality of life of breast cancer patients. It permits to evaluate the symptoms of breast cancer and the side effects of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cosmetics Evaluation</measure>
    <time_frame>3 years</time_frame>
    <description>cosmetic results will be evaluated by centralized photographic analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">666</enrollment>
  <condition>DCIS</condition>
  <condition>Breast Cancer</condition>
  <condition>Low Risk DCIS</condition>
  <condition>Breast Conserving Surgery</condition>
  <condition>Radiotherapy Omission</condition>
  <arm_group>
    <arm_group_label>Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>No Irradiation- Active surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>two fractionation regimens will be allowed for whole-breast irradiation: 50 Gy in 25 fractions over 5 weeks or 40 Gy in 15 fractions over 3 weeks. The delivery of an additional dose to the tumour bed (boost) will be at the referring physician discretion, according to the guidelines</description>
    <arm_group_label>Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Radiotherapy</intervention_name>
    <description>No Irradiation- Active surveillance</description>
    <arm_group_label>No Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Woman aged ≥50 years,&#xD;
&#xD;
          2. ECOG performance status ≤2&#xD;
&#xD;
          3. Microcalcifications on pre-biopsy mammography, unifocal, ≤25 mm or opacity without&#xD;
             microcalcifications and no clinical palpable tumour&#xD;
&#xD;
          4. Absence of suspicious residual microcalcifications either on post-biopsy/ preoperative&#xD;
             localization mammography, or on post-operative mammography Note: if absence of&#xD;
             residual microcalcifications on post-biopsy/pre-operative mammography, post-operative&#xD;
             mammography is not mandatory;&#xD;
&#xD;
          5. Breast-conserving surgical excision;&#xD;
&#xD;
          6. Histologically proven DCIS of the breast without an invasive component; Note&#xD;
             Incidental histological finding of DCIS lesions developed within a benign breast&#xD;
             lesion as well as an association with classical lobular carcinoma in situ (LCIS)&#xD;
             associated with the DCIS are accepted.&#xD;
&#xD;
          7. Free margins (≥2 mm), or free margins following re-excision;&#xD;
&#xD;
          8. Low or Intermediate nuclear grade; Note: In case of nuclear grade heterogeneity within&#xD;
             the same sample or between the biopsy or the surgical specimen, the highest nuclear&#xD;
             grade score will prevail.&#xD;
&#xD;
          9. Tumour tissue sample availability; Note: Surgical specimen is mandatory unless no&#xD;
             residual disease on the surgical specimen. In this instance, the initial diagnosis&#xD;
             biopsy is required.&#xD;
&#xD;
         10. Absence of extensive necrosis (≤30% of the lumen diameter);&#xD;
&#xD;
         11. Immunohistochemical characteristics of luminal A subtype: ER≥10 %, PR ≥20 %, HER2&#xD;
             negative (0/1+) or 2+ not amplified (confirmed by fluorescent in situ hybridization&#xD;
             (FISH) or chromogenic in situ hybridization (CISH)), Ki67 &lt;15%.&#xD;
&#xD;
         12. Patient willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment, scheduled visits and examinations and including&#xD;
             follow-up;&#xD;
&#xD;
         13. Written informed consent.&#xD;
&#xD;
         14. Affiliation to the French social security.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Endocrine treatment for breast cancer.&#xD;
&#xD;
          2. Previous invasive breast cancer including contralateral breast cancer, either&#xD;
             metachronous or synchronous&#xD;
&#xD;
          3. Previous DCIS except contralateral DCIS in complete and continuous remission for more&#xD;
             than 5 years&#xD;
&#xD;
          4. Previous other cancers (except basal-cell, carcinoma in situ of the cervix or&#xD;
             endometrium), not in complete and continuous remission for more than 10 years&#xD;
&#xD;
          5. Known breast-cancer predisposing germ-cell mutation;&#xD;
&#xD;
          6. Palpable tumour with a diagnosis of DCIS on biopsy&#xD;
&#xD;
          7. Bloody nipple discharge;&#xD;
&#xD;
          8. Histological size &gt;25 mm in one or multiple foci&#xD;
&#xD;
          9. High nuclear grade, including high nuclear grade in heterogeneous tumours;either on&#xD;
             biopsy or on surgical specimen&#xD;
&#xD;
         10. Associated microinvasive or invasive component;&#xD;
&#xD;
         11. Presence of tumour cells in lymph nodes detected using H&amp;E or immunohistochemical&#xD;
             examination (if lymph node sentinel biopsy or dissection has been performed);&#xD;
&#xD;
         12. Absolute contra-indication to whole-breast irradiation as determined by the referring&#xD;
             physician;&#xD;
&#xD;
         13. Patient unable to comply with study obligations for geographic, social, or physical&#xD;
             reasons, or who is unable to understand the purpose and procedures of the study.&#xD;
&#xD;
         14. Pregnant women or breast feeding mothers,&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alain FOURQUET, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie BERGEAUD, PhD</last_name>
    <phone>+33 1 73 77 54 38</phone>
    <email>m-bergeaud@unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Assia LAMRANI-GHAOUTI, PhD</last_name>
    <email>a-lamrani-ghaouti@unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest -Site Paul Papin</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurore GOINEAU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine ARNAUD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christel BRETON CALLU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien GEFFRELOT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Cotentin</name>
      <address>
        <city>Cherbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure KALUZINSKI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie BELLIERE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine PEIGNAUX, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier De Lagny Sur Marne</name>
      <address>
        <city>Jossigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estelle WAFO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David PASQUIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu De Limoges - Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre CLAVERE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume BERA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Violaine BENEYTON, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marion CORTET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Regional Du Cancer Montpellier Val D Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire LEMANSKI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Eve CHAND FOUCHE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre de Haute Energie</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie PINTO, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MAINGON, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut CURIE</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain FOURQUET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Adrien BOLZE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle LECOUILLARD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Frédéric Joliot</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine MEZZANI SAILLARD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal HANZEN, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital René Huguenin - Institut Curie</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain FOURQUET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inès MENOUX, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ciprian CHIRA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut De Cancerologie De Lorraine Alexis Vautrin</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam KHADIGE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofia RIVERA, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>July 28, 2021</last_update_submitted>
  <last_update_submitted_qc>July 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

